Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study

被引:0
作者
Celine Miyazaki
Yutaka Ishii
Natalia M. Stelmaszuk
机构
[1] Janssen Pharmaceutical K.K.,Health Economics Department
[2] Janssen Pharmaceutical K.K.,Immunology, Infectious Diseases and Vaccine Department, Medical Affairs Division
[3] Parexel International,Real World Evidence Consultant
来源
Clinical Rheumatology | 2022年 / 41卷
关键词
Dermatomyositis; Healthcare resource utilization; Polymyositis; Treatment choice;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:741 / 755
页数:14
相关论文
共 224 条
[1]  
Findlay AR(2015)An overview of polymyositis and dermatomyositis Muscle Nerve 51 638-656
[2]  
Goyal NA(2018)Classification of myositis Nat Rev Rheumatol 14 269-278
[3]  
Mozaffar T(2015)Inflammatory muscle diseases N Engl J Med 372 1734-1747
[4]  
Lundberg IE(2011)Therapy of polymyositis and dermatomyositis Autoimmun Rev 11 6-13
[5]  
de Visser M(2019)Polymyositis and dermatomyositis - challenges in diagnosis and management J Transl Autoimmun 2 477-480
[6]  
Werth VP(2014)Prevalence and incidence of polymyositis and dermatomyositis in Japan Mod Rheumatol 24 759-764
[7]  
Dalakas MC(2013)Age at onset and gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and systemic sclerosis in Japan Mod Rheumatol 23 3-21
[8]  
Marie I(2019)Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists Neurol Clin Neurosci 7 971-982
[9]  
Mouthon L(2003)Polymyositis and dermatomyositis Lancet 362 314-324
[10]  
Yang SH(2013)Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial Arthritis Rheum 65 1424-1433